InMed Pharmaceuticals price to sales ratio INM

Market value divided by revenue over the last twelve months, since 2022.

Today, Oct 23, 2026: n/m; not a meaningful number
Last meaningful: 1.0×; Sep 2026
4-year median: 0.7×
4-year range: 0.2× to 2.7×
Peer median: 0.9×

InMed Pharmaceuticals' price to sales ratio is not a meaningful number today: revenue for one or more of the four quarters through 2026-06-30 is missing, so twelve months can't be added up.

It was last meaningful in Sep 2026, at 1.0×.

On the days it had one over the last 4 years, its median was 0.7×, from 0.2× in Aug 2024 to 2.7× in Feb 2023.

Price to sales ratio over time

Open the interactive chart, with overlays and comparisons

Year by year

Year	End of year	Low	High
2026 so far	1.0×	0.4×	1.3×
2025	0.7×	0.4×	1.1×
2024	0.7×	0.2×	1.0×
2023	0.5×	0.3×	2.7×
2022	1.3×	0.9×	1.9×

Against its peers

Companies in Drug Manufacturers - General nearest InMed Pharmaceuticals' size, closest first, today.

Company	Price to sales ratio
INMInMed Pharmaceuticals	n/m
ATNMActinium Pharmaceuticals	n/m
SPROSpero Therapeutics	1.4×
LFVNLifevantage	0.4×
Peer median	0.9×

What the price to sales ratio tells you

Market value divided by revenue over the last twelve months. Useful for companies with little or no profit yet, since sales are harder to make negative than earnings.

Ignores margins entirely. A software company at 10× sales with 30% margins can be cheaper than a grocer at 1× sales with 2% margins.

More on InMed Pharmaceuticals

Valuation data, not investment advice. Prices as of Oct 23, 2026. Reported figures come from the company's filings with the SEC.